<DOC>
	<DOCNO>NCT02582476</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled phase II clinical trial cross-over design investigate efficacy bumetanide patient hypokalemic periodic paralysis ( HypoPP ) . The aim ass efficacy bumetanide reduce severity duration focal attack weakness hand muscle . Twelve participant recruit .</brief_summary>
	<brief_title>Bumetanide Hypokalaemic Periodic Paralysis</brief_title>
	<detailed_description>Interested patient provisionally meet inclusion/exclusion criterion attend NHNN screen visit check study eligibility question relate study participation answer . Each patient undertake two assessment visit approximately four week apart . Study participant withhold carbonic anhydrase inhibitor medication 72 hour prior assessment visit standard McManis test restart routine treatment immediately visit . Participants admit NHNN day case . Following baseline assessment localise attack weakness induce isometric exercise abductor digit minimi ( ADM ) hand per McManis protocol . Participants randomly assign either bumetanide placebo first visit . Identical appear capsule prepare blind researcher participant treatment allocation . The assigned treatment take mouth onset focal attack define 40 % decrement ADM CMAP amplitude compare maximum CMAP amplitude record exercise . During admission patient monitor accord research protocol . At end assessment protocol participant discharge home . The duration admission approximately 6 hour The second assessment follow identical protocol first , treatment administer .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Hypokalemic Periodic Paralysis</mesh_term>
	<mesh_term>Bumetanide</mesh_term>
	<criteria>At least 18 year age ; Diagnosis genetically confirm HypoPP ; Clinical symptom sign active symptomatic disease ( least 1 attack last 12 month ) ; Practising acceptable method birth control duration trial . This addressed Patient Information Sheet men woman ( section 11.4.5 ) ; Inability unwillingness provide inform consent ; People older 64 year old ; Other condition cause hand weakness could interfere study measurement ( e.g . due stroke , trauma arthritis ) Patients history cardiac disease , renal failure moderate severe hepatic disease . Note : abnormality serum transaminase common people HypoPP arise skeletal muscle rather specific liver abnormality . Consequently , raise serum bilirubin &gt; 20 % baseline value use identify abnormal liver function ; Women pregnant breastfeeding ; Patients current previous history diabetes , porphyria , symptomatic hypotension , prostatic hypertrophy difficulty micturition , allergy sulfonamide thiazide ; Patients lithium , digoxin , nephro ototoxic drug ; Patients know allergic bumetanide excipients ; Patients history inadequately treat Addison 's disease ; Patients participate another interventional trial previous 1 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypokalemic Periodic Paralysis</keyword>
	<keyword>Bumetanide</keyword>
	<keyword>Periodic Paralysis</keyword>
</DOC>